Novel d-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral κ-opioid receptors,

Todd W Vanderah, Tally Largent-Milnes, Josephine Lai, Frank Porreca, Richard A. Houghten, Frédérique Menzaghi, Kazimierz Wisniewski, Jacek Stalewski, Javier Sueiras-Diaz, Robert Galyean, Claudio Schteingart, Jean Louis Junien, Jerzy Trojnar, Pierre J M Rivière

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Kappa-(κ) opioid receptors are widely distributed in the periphery and activation results in antinociception; however supraspinal acting κ-agonists result in unwanted side effects. Two novel, all d-amino acid, tetrapeptide κ-opioid receptor agonists, FE 200665 and FE 200666, were identified and compared to brain penetrating (enadoline) and peripherally selective (asimadoline) κ-agonists as potential analgesics lacking unwanted central nervous system (CNS) side effects. In vitro characterization was performed using radioligand binding and GTPγS binding. Antinociception was evaluated in both mice and rats. Rotarod tests were performed to determine motor impairment effects of the κ-agonists. FE 200665 and FE 200666 showed high affinity for human κ-opioid receptor 1 (Ki of 0.24 nM and 0.08 nM, respectively) and selectivity for human κ-opioid receptor 1 (human κ-opioid receptor 1/human μ-opioid receptor/humanδ-opioid receptor selectivity ratios of 1/16,900/84,600 and 1/88,600/> 1,250,000, respectively). Both compounds demonstrated agonist activity in the human κ-opioid receptor 1 [35S]GTPγS binding assay (EC50 of 0.08 nM and 0.03 nM) and resulted in dose-related antinociception in the mouse writhing test (A50: 0.007 and 0.013 mg/kg, i.v., respectively). Markedly higher doses of FE 200665 and FE 200666 were required to induce centrally-mediated effects in the rotarod assay (548- and 182-fold higher doses, respectively), and antinociception determined in the mouse tail-flick assay (> 1429- and 430-fold fold higher doses, respectively) after peripheral administration supporting a peripheral site of action. The potency ratios between central and peripheral activity suggest a therapeutic window significantly higher than previous κ-agonists. Furthermore, FE 200665 has entered into clinical trials with great promise as a novel analgesic lacking unwanted side effects seen with current therapeutics.

Original languageEnglish (US)
Pages (from-to)62-72
Number of pages11
JournalEuropean Journal of Pharmacology
Volume583
Issue number1
DOIs
StatePublished - Mar 31 2008

Fingerprint

Opioid Receptors
Amino Acids
Rotarod Performance Test
Analgesics
kappa Opioid Receptor
Human Activities
Tail
Central Nervous System
Clinical Trials
D-phenylalanyl-D-phenylalanyl-D-norleucyl-N-(4-pyridinylmethyl)-d-argininamide
Brain
Therapeutics
FE 200666

Keywords

  • Antinociception
  • Kappa opioid agonist
  • Peptides
  • Peripheral
  • Radioligand binding
  • Rodent models

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Novel d-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral κ-opioid receptors,. / Vanderah, Todd W; Largent-Milnes, Tally; Lai, Josephine; Porreca, Frank; Houghten, Richard A.; Menzaghi, Frédérique; Wisniewski, Kazimierz; Stalewski, Jacek; Sueiras-Diaz, Javier; Galyean, Robert; Schteingart, Claudio; Junien, Jean Louis; Trojnar, Jerzy; Rivière, Pierre J M.

In: European Journal of Pharmacology, Vol. 583, No. 1, 31.03.2008, p. 62-72.

Research output: Contribution to journalArticle

Vanderah, TW, Largent-Milnes, T, Lai, J, Porreca, F, Houghten, RA, Menzaghi, F, Wisniewski, K, Stalewski, J, Sueiras-Diaz, J, Galyean, R, Schteingart, C, Junien, JL, Trojnar, J & Rivière, PJM 2008, 'Novel d-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral κ-opioid receptors,', European Journal of Pharmacology, vol. 583, no. 1, pp. 62-72. https://doi.org/10.1016/j.ejphar.2008.01.011
Vanderah, Todd W ; Largent-Milnes, Tally ; Lai, Josephine ; Porreca, Frank ; Houghten, Richard A. ; Menzaghi, Frédérique ; Wisniewski, Kazimierz ; Stalewski, Jacek ; Sueiras-Diaz, Javier ; Galyean, Robert ; Schteingart, Claudio ; Junien, Jean Louis ; Trojnar, Jerzy ; Rivière, Pierre J M. / Novel d-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral κ-opioid receptors,. In: European Journal of Pharmacology. 2008 ; Vol. 583, No. 1. pp. 62-72.
@article{78b48fc56aff4386bf9af9a6a5a37ada,
title = "Novel d-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral κ-opioid receptors,",
abstract = "Kappa-(κ) opioid receptors are widely distributed in the periphery and activation results in antinociception; however supraspinal acting κ-agonists result in unwanted side effects. Two novel, all d-amino acid, tetrapeptide κ-opioid receptor agonists, FE 200665 and FE 200666, were identified and compared to brain penetrating (enadoline) and peripherally selective (asimadoline) κ-agonists as potential analgesics lacking unwanted central nervous system (CNS) side effects. In vitro characterization was performed using radioligand binding and GTPγS binding. Antinociception was evaluated in both mice and rats. Rotarod tests were performed to determine motor impairment effects of the κ-agonists. FE 200665 and FE 200666 showed high affinity for human κ-opioid receptor 1 (Ki of 0.24 nM and 0.08 nM, respectively) and selectivity for human κ-opioid receptor 1 (human κ-opioid receptor 1/human μ-opioid receptor/humanδ-opioid receptor selectivity ratios of 1/16,900/84,600 and 1/88,600/> 1,250,000, respectively). Both compounds demonstrated agonist activity in the human κ-opioid receptor 1 [35S]GTPγS binding assay (EC50 of 0.08 nM and 0.03 nM) and resulted in dose-related antinociception in the mouse writhing test (A50: 0.007 and 0.013 mg/kg, i.v., respectively). Markedly higher doses of FE 200665 and FE 200666 were required to induce centrally-mediated effects in the rotarod assay (548- and 182-fold higher doses, respectively), and antinociception determined in the mouse tail-flick assay (> 1429- and 430-fold fold higher doses, respectively) after peripheral administration supporting a peripheral site of action. The potency ratios between central and peripheral activity suggest a therapeutic window significantly higher than previous κ-agonists. Furthermore, FE 200665 has entered into clinical trials with great promise as a novel analgesic lacking unwanted side effects seen with current therapeutics.",
keywords = "Antinociception, Kappa opioid agonist, Peptides, Peripheral, Radioligand binding, Rodent models",
author = "Vanderah, {Todd W} and Tally Largent-Milnes and Josephine Lai and Frank Porreca and Houghten, {Richard A.} and Fr{\'e}d{\'e}rique Menzaghi and Kazimierz Wisniewski and Jacek Stalewski and Javier Sueiras-Diaz and Robert Galyean and Claudio Schteingart and Junien, {Jean Louis} and Jerzy Trojnar and Rivi{\`e}re, {Pierre J M}",
year = "2008",
month = "3",
day = "31",
doi = "10.1016/j.ejphar.2008.01.011",
language = "English (US)",
volume = "583",
pages = "62--72",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Novel d-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral κ-opioid receptors,

AU - Vanderah, Todd W

AU - Largent-Milnes, Tally

AU - Lai, Josephine

AU - Porreca, Frank

AU - Houghten, Richard A.

AU - Menzaghi, Frédérique

AU - Wisniewski, Kazimierz

AU - Stalewski, Jacek

AU - Sueiras-Diaz, Javier

AU - Galyean, Robert

AU - Schteingart, Claudio

AU - Junien, Jean Louis

AU - Trojnar, Jerzy

AU - Rivière, Pierre J M

PY - 2008/3/31

Y1 - 2008/3/31

N2 - Kappa-(κ) opioid receptors are widely distributed in the periphery and activation results in antinociception; however supraspinal acting κ-agonists result in unwanted side effects. Two novel, all d-amino acid, tetrapeptide κ-opioid receptor agonists, FE 200665 and FE 200666, were identified and compared to brain penetrating (enadoline) and peripherally selective (asimadoline) κ-agonists as potential analgesics lacking unwanted central nervous system (CNS) side effects. In vitro characterization was performed using radioligand binding and GTPγS binding. Antinociception was evaluated in both mice and rats. Rotarod tests were performed to determine motor impairment effects of the κ-agonists. FE 200665 and FE 200666 showed high affinity for human κ-opioid receptor 1 (Ki of 0.24 nM and 0.08 nM, respectively) and selectivity for human κ-opioid receptor 1 (human κ-opioid receptor 1/human μ-opioid receptor/humanδ-opioid receptor selectivity ratios of 1/16,900/84,600 and 1/88,600/> 1,250,000, respectively). Both compounds demonstrated agonist activity in the human κ-opioid receptor 1 [35S]GTPγS binding assay (EC50 of 0.08 nM and 0.03 nM) and resulted in dose-related antinociception in the mouse writhing test (A50: 0.007 and 0.013 mg/kg, i.v., respectively). Markedly higher doses of FE 200665 and FE 200666 were required to induce centrally-mediated effects in the rotarod assay (548- and 182-fold higher doses, respectively), and antinociception determined in the mouse tail-flick assay (> 1429- and 430-fold fold higher doses, respectively) after peripheral administration supporting a peripheral site of action. The potency ratios between central and peripheral activity suggest a therapeutic window significantly higher than previous κ-agonists. Furthermore, FE 200665 has entered into clinical trials with great promise as a novel analgesic lacking unwanted side effects seen with current therapeutics.

AB - Kappa-(κ) opioid receptors are widely distributed in the periphery and activation results in antinociception; however supraspinal acting κ-agonists result in unwanted side effects. Two novel, all d-amino acid, tetrapeptide κ-opioid receptor agonists, FE 200665 and FE 200666, were identified and compared to brain penetrating (enadoline) and peripherally selective (asimadoline) κ-agonists as potential analgesics lacking unwanted central nervous system (CNS) side effects. In vitro characterization was performed using radioligand binding and GTPγS binding. Antinociception was evaluated in both mice and rats. Rotarod tests were performed to determine motor impairment effects of the κ-agonists. FE 200665 and FE 200666 showed high affinity for human κ-opioid receptor 1 (Ki of 0.24 nM and 0.08 nM, respectively) and selectivity for human κ-opioid receptor 1 (human κ-opioid receptor 1/human μ-opioid receptor/humanδ-opioid receptor selectivity ratios of 1/16,900/84,600 and 1/88,600/> 1,250,000, respectively). Both compounds demonstrated agonist activity in the human κ-opioid receptor 1 [35S]GTPγS binding assay (EC50 of 0.08 nM and 0.03 nM) and resulted in dose-related antinociception in the mouse writhing test (A50: 0.007 and 0.013 mg/kg, i.v., respectively). Markedly higher doses of FE 200665 and FE 200666 were required to induce centrally-mediated effects in the rotarod assay (548- and 182-fold higher doses, respectively), and antinociception determined in the mouse tail-flick assay (> 1429- and 430-fold fold higher doses, respectively) after peripheral administration supporting a peripheral site of action. The potency ratios between central and peripheral activity suggest a therapeutic window significantly higher than previous κ-agonists. Furthermore, FE 200665 has entered into clinical trials with great promise as a novel analgesic lacking unwanted side effects seen with current therapeutics.

KW - Antinociception

KW - Kappa opioid agonist

KW - Peptides

KW - Peripheral

KW - Radioligand binding

KW - Rodent models

UR - http://www.scopus.com/inward/record.url?scp=39749124835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749124835&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2008.01.011

DO - 10.1016/j.ejphar.2008.01.011

M3 - Article

C2 - 18282565

AN - SCOPUS:39749124835

VL - 583

SP - 62

EP - 72

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -